Search

Your search keyword '"Zukotynski K"' showing total 142 results

Search Constraints

Start Over You searched for: Author "Zukotynski K" Remove constraint Author: "Zukotynski K"
142 results on '"Zukotynski K"'

Search Results

51. Role of Artificial Intelligence in Theranostics:: Toward Routine Personalized Radiopharmaceutical Therapies.

52. Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects.

53. A Radiology-focused Review of Predictive Uncertainty for AI Interpretability in Computer-assisted Segmentation.

55. Detecting lumbar lesions in 99m Tc-MDP SPECT by deep learning: Comparison with physicians.

56. Exploratory Assessment of K-means Clustering to Classify 18F-Flutemetamol Brain PET as Positive or Negative.

57. Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy.

58. Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician's guide.

59. Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer.

60. CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment.

61. Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy.

62. Machine Learning in Nuclear Medicine: Part 2-Neural Networks and Clinical Aspects.

64. Radiographic and metabolic evolution of prostate cancer lung metastasis detected by prostate-specific membrane antigen and fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.

65. Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18 F-DCFPyL PET/CT Restaging.

66. The Use of Random Forests to Identify Brain Regions on Amyloid and FDG PET Associated With MoCA Score.

68. Clinical and Technical Considerations for Brain PET Imaging for Dementia.

69. A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy.

71. The Use of Random Forests to Classify Amyloid Brain PET.

73. Use of a Qualification Phantom for PET Brain Imaging in a Multicenter Consortium: A Collaboration Between the Pediatric Brain Tumor Consortium and the SNMMI Clinical Trials Network.

74. Machine Learning in Nuclear Medicine: Part 1-Introduction.

75. Update 2018: 18F-FDG PET/CT and PET/MRI in Head and Neck Cancer.

76. Harmonization of United States, European Union and Canadian First-in-Human Regulatory Requirements for Radiopharmaceuticals-Is This Possible?

77. PET/CT of Dementia.

79. Pulmonary nodules as incidental findings.

80. Appropriate Use Criteria for 18 F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease.

81. Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.

82. Joint reconstruction of Ictal/inter-ictal SPECT data for improved epileptic foci localization.

84. Response Assessment Criteria and Their Applications in Lymphoma: Part 2.

85. Response Assessment Criteria and Their Applications in Lymphoma: Part 1.

86. Targeted Radionuclide Therapy: Practical Applications and Future Prospects.

87. Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: From chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases.

88. Proceedings of the Second NCI-SNMMI Workshop on Targeted Radionuclide Therapy.

89. Beyond current guidelines: reduction in minimum administered radiopharmaceutical activity with preserved diagnostic image quality in pediatric hepatobiliary scintigraphy.

90. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.

91. 18F-FDG PET and MR imaging associations across a spectrum of pediatric brain tumors: a report from the pediatric brain tumor consortium.

92. Abdomen: normal variations and benign conditions resulting in uptake on FDG-PET/CT.

93. Targeted radionuclide therapy: proceedings of a joint workshop hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging.

94. Imaging in prostate carcinoma.

95. Anal carcinoma: FDG PET/CT in staging, response evaluation, and follow-up.

96. Update on imaging of vulvar squamous cell carcinoma.

97. Imaging features of primary and secondary adult rhabdomyosarcoma.

98. MRI for evaluation of myeloid sarcoma in adults: a single-institution 10-year experience.

99. PET/CT and renal pathology: a blind spot for radiologists? Part 1, primary pathology.

100. PET/CT and renal pathology: a blind spot for radiologists? Part 2--lymphoma, leukemia, and metastatic disease.

Catalog

Books, media, physical & digital resources